Skip to Content

Revatio Approval History

FDA Approved: Yes (First approved June 3, 2005)
Brand name: Revatio
Generic name: sildenafil citrate
Company: Pfizer Inc.
Treatment for: Pulmonary Hypertension

Revatio (sildenafil) is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension.

Development History and FDA Approval Process for Revatio

DateArticle
Nov 20, 2009Approval FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Jun  3, 2005Approval Revatio Pfizer Inc. - Treatment for Pulmonary Arterial Hypertension
Dec  3, 2004Pfizer Submits Regulatory Filings for Revatio as a Treatment for Pulmonary Arterial Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide